Please login to the form below

Not currently logged in
Email:
Password:

Dr Keith Bragman joins Alacrita

He becomes a partner at the firm’s London office

Alacrita Dr Keith BragmanLife sciences consultancy Alacrita has appointed Dr Keith Bragman as a partner in its London office.

Dr Bragman brings a wealth of industry experience to the firm, having served on the Science and Technology Select Committee at the House of Commons, worked with the Bill and Melinda Gates Foundation and at the UK government's department for international development.

He has held a number of senior leadership positions at pharmaceutical companies, including serving as head of global development and research for UCB's Japanese business, vice president and senior partner for biotechnology at Quintiles, and European head of clinical oncology at Bristol-Myers Squibb.

Managing partner Anthony Walker said: “We are delighted to welcome Keith to our product development practice as we build a best-in-class consulting practice to help companies develop better therapeutics.

“Keith is an experienced executive with deep and broad knowledge of the drug development process and a sound understanding of the challenges faced by senior management.

“He joins a high calibre team of seasoned consultants and underlines our commitment to providing exceptionally high quality advice to the industry.”

30th June 2016

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics